Concerning improving diversity in clinical trials.
Summary
Requires the University of Washington, Washington State University, and any hospital or state agency that receives National Institutes of Health funding for drug and medical device clinical trials to offer information in a language other than English, to provide culturally specific recruitment materials, and to provide electronic consent when available.
Codifies the Washington State Institutional Review Board (Review Board).
Requires the Review Board and the Andy Hill Cancer Research Endowment to consider in their evaluation four factors related to increasing participation of underrepresented communities in clinical trials of drugs and medical devices.
Requires the Department of Health, in consultation with research and community-based entities, to study and provide recommendations on increasing access to clinical trials and participation in clinical trials by persons who are members of underrepresented communities.
From the Substitute House Bill Report (SSB 5388), written by the Legislature's nonpartisan staff. Read the full report ↗
Did not passDid not pass · passed Senate, stalled in House